Morgan Lee Lekstrom Buys 20,000 Shares of Biosig Technologies (NASDAQ:STEX) Stock

Biosig Technologies, Inc. (NASDAQ:STEX) Chairman Morgan Lee Lekstrom acquired 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was purchased at an average cost of $2.50 per share, with a total value of $50,000.00. Following the acquisition, the chairman directly owned 122,500 shares of the company’s stock, valued at $306,250. This trade represents a 19.51% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Tuesday, February 3rd, Morgan Lee Lekstrom bought 23,500 shares of Biosig Technologies stock. The stock was purchased at an average cost of $3.06 per share, for a total transaction of $71,910.00.
• On Thursday, January 29th, Morgan Lee Lekstrom purchased 2,500 shares of Biosig Technologies stock. The shares were purchased at an average price of $3.70 per share, with a total value of $9,250.00.
• On Monday, January 26th, Morgan Lee Lekstrom purchased 23,000 shares of Biosig Technologies stock. The shares were acquired at an average cost of $3.30 per share, with a total value of $75,900.00.
• On Tuesday, January 27th, Morgan Lee Lekstrom acquired 5,500 shares of Biosig Technologies stock. The stock was acquired at an average cost of $3.12 per share, for a total transaction of $17,160.00.
• On Friday, January 23rd, Morgan Lee Lekstrom bought 41,000 shares of Biosig Technologies stock. The shares were acquired at an average price of $3.13 per share, with a total value of $128,330.00.

Biosig Technologies Stock Performance

STEX opened at $2.30 on Friday. The company has a market capitalization of $367.08 million, a price-to-earnings ratio of -1.70 and a beta of 1.50. Biosig Technologies, Inc. has a 1-year low of $0.40 and a 1-year high of $14.11.

Wall Street Analyst Weigh In

Separately, Weiss Ratings initiated coverage on Biosig Technologies in a research note on Friday, January 23rd. They issued a “sell (d-)” rating on the stock. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.